Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
- Resource Type
- Article
- Source
- The Lancet Haematology; 20240101, Issue: Preprints
- Subject
- Language
- ISSN
- 23523026